



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

April 12, 2021

Eric Dobmeier
President and Chief Executive Officer
Chinook Therapeutics, Inc.
1600 Fairview Avenue East, Suite 100
Seattle, WA 98102

Re: Chinook Therapeutics, Inc.
Registration Statement on Form S-3
Filed April 7, 2021
File No. 333-255099

Dear Mr. Dobmeier:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Dillon Hagius at 202-551-7967 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Ryan Mitteness